AIVITA Biomedical

Hans Keirstead, Ph.D., CEO
Irvine, CA
AIVITA Biomedical is a personalized vaccine company designing immuno-oncology therapies that target the seed of all cancers: tumor-initiating cells. We take a unique pan-antigenic approach — targeting all neoantigens, rather than a select few — allowing our treatments to overcome cancer’s tendency to mutate over time. Our patient-specific treatments have shown tremendous promise in eradicating tumors without harmful side effects in our melanoma and glioblastoma clinical studies. We have also leveraged our approach to create a proprietary skincare line, which dedicates 100% of net proceeds towards advancing revolutionary treatments for patients with cancer, and continue to explore additional applications in human health.

By using this website you agree to accept our Privacy Policy and Terms & Conditions